Bicara Therapeutics Inc. Common Stock (BCAX)vsRevolution Medicines Inc (RVMD)
BCAX
Bicara Therapeutics Inc. Common Stock
$9.76
-44.16%
HEALTHCARE · Cap: $1.11B
RVMD
Revolution Medicines Inc
$188.72
+1.34%
HEALTHCARE · Cap: $38.14B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. BCAX earns a higher WallStSmart Score of 28/100 (F).
BCAX
Avoid28
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 15.5x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : BCAX
The strongest argument for BCAX centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : BCAX
The primary concerns for BCAX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.40 — expect wider price swings.
BCAX is growing revenue faster at 0.0% — sustainability is the question.
BCAX generates stronger free cash flow (-44M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BCAX scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bicara Therapeutics Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. The company is headquartered in Boston, Massachusetts.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?